You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Preclinical development of novel small molecule malaria drugs that overcome drug
SBC: DESIGNMEDIX, INC. Topic: NIAIDDESCRIPTION provided by applicant The worldwide health problem created by malaria has been made more difficult by the spread of drug resistant parasites We have developed an orally available and inexpensive class of novel drugs that act against both chloroquine resistant and chloroquine sensitive malaria This project carries on preclinical development of a drug candidate that has been select ...
STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health -
Proteasome inhibitor re-sensitizing molecules for treatment of refractory multiple myeloma
SBC: LEUKOGENE THERAPEUTICS INC Topic: 102Project Summary Abstract Multiple MyelomaMMis the second most common form of blood cancer and remains an incurable and deadly diseaseProteasome inhibitorPItherapy is a cornerstone in the treatment of MMbut resistance to this class of agent is an emerging challenge in the clinicNew therapeutic approaches that specifically target resistance are needed to maximize responses and ultimately produce cur ...
STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Aminoglycosides with reduced ototoxicity
SBC: NUBAD LLC Topic: NIAIDPROJECT SUMMARYAminoglycosides are one of the cheapest and well-known antibiotics in clinical use for over 70 years, but one of the major limitations in their use is their ototoxicity. We are developing fast and low-cost methods to develop aminoglycosides with anti-ribosomal activities and reduced toxicity. In this project, we will identify novel aminoglycoside antibacterials, that show reduced ot ...
STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health -
Development of peptide nucleic acid antibiotics
SBC: NUBAD LLC Topic: NIAIDThe world is rapidly heading towards a pre-1940’s scenario when it comes to fighting infectious disease. Antimicrobial resistance is a growing problem on a global scale, greatly hampering our abilities to quell worldwide epidemics such as influenza, SARS, COVID-19, tuberculosis and malaria, as well as the simple staphylococcus infection. Unless innovative strategies are developed to produce robu ...
STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health -
Portable, affordable, quantitative microchip electrophoresis for hemoglobin A1C testing
SBC: HEMEX HEALTH INC Topic: 200PROJECT SUMMARY Diabetes is one of the most important health issues in the world. The number of people living with diabetes has quadrupled since 1980, with the greatest increase in prevalence in low and middle-income countries. Not only is diabetes a major cause of morbidity and mortality, but it can also devastate the finances of families and strain countries’ financial resources. World Health ...
STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health -
Mitigating Injurious Falls in Older Adults Through Non-Injurious Fall and Gait Analysis From Floor Vibrations
SBC: ADVANCED SMART SYSTEMS AND EVALUATION TECHNOLOGIES, LLC Topic: NIAProject Summary and Abstract Falls are the leading cause of death due to injury. Falls are so common that 30% of community dwelling older adults, and 50% of residents in Care Facilities will experience a fall in the coming year. The risk of falling substantially increases for those having Alzheimer’s disease and related dementias. The financial burden is significant with fall-related costs being ...
STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health -
Development of Novel Compounds for Treatment of Heart Arrhythmias in CPVT
SBC: Elex Biotech, Inc Topic: NHLBIDESCRIPTION provided by applicant Abstract Current therapies to treat the orphan disease catecholaminergic polymorphic ventricular tachycardia CPVT have potential side effects so severe that hospitalization is required upon treatment initiation and severely exacerbate depression and fatigue in children that already have psychological issues due to this devastating life long life threaten ...
STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health -
Stroke Treatment by Chemically-induced Hypothermia
SBC: JT Pharmaceuticals, Inc. Topic: 101DESCRIPTION provided by applicant Stroke is a leading cause of human death and disability in the United States while clinical therapy for acute stroke is limited and unsatisfactoy The many failures in clinical trials strongly endorse the idea that to battle this multifaceted bran disorder novel strategies that target multiple cell types and different mechanisms are needed to achieve therapeut ...
STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health -
A Short Instrumented Test of Mobility for Neurological Disorders
SBC: APDM, INC. Topic: NICHDDESCRIPTION provided by applicant APDM is a young company focused on developing and commercializing professional systems using wearable inertial sensors for monitoring of human movement and movement disorders In Phase I we developed the novel Instrumented Stand and Walk test ISAW using APDMandapos s proprietary Opal movement monitors and Mobility Lab system We validated the ISAW by demon ...
STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health -
Development of DR?1-MOG-35-55 for treatment of DR2 negative MS subjects
SBC: VIROGENOMICS BIODEVELOPMENT INC Topic: NIAIDPROJECT SUMMARY ABSTRACT Our recently completed Phaseanimal studies demonstrated the ability of our novel second generation partialp MHC constructDRhMOGto treat acute and chronic EAE with potency comparable to the parent RTLmoleculepDRMOGin matched DRTg mice and in DRnegative mismatched miceHaving met our Phasemilestonesour Phase II application will produce a fully humanized DRhMOGmolecule and ass ...
STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health